U.S. FDA approves first mRNA flu shot from Moderna

• Health Canada has approved a Phase I clinical trial for Moderna’s mRNA vaccine candidate targeting the Bundibugyo virus, a species of Ebola. • Canada becomes the second nation to authorize this trial, following a similar approval in the United Kingdom.

• Health officials have approved mFLUSIVA, the first mRNA-based flu vaccine developed by Moderna, which is expected to be available by the next flu season. • Clinical data indicates the shot may be 27% more effective than traditional vaccines, though side effects like fatigue and headaches occurred in up to two-thirds of patients.

• On July 30, 2026, Health Canada authorized Moderna to begin a Phase I clinical trial for a candidate mRNA vaccine targeting the Bundibugyo virus, a cause of Ebola disease. • The trial will evaluate whether the candidate vaccine triggers the production of antibodies in participants' immune systems to fight the virus.

• The FDA has approved mFlusiva, the first mRNA-based influenza vaccine developed by Moderna, specifically targeting adults aged 50 and older. • The regulatory strategy includes full approval for adults aged 50 to 64 and accelerated approval for those 65 and older, pending a postmarketing study using a high-dose comparator.

• The author argues that modern medical science has shifted from seeking truth to protecting a "medical monopoly," leading to the suppression of effective therapies like chlorine dioxide. • The text criticizes the reliance on expensive randomized controlled trials (RCTs), claiming they are often manipulated by sponsors to artificially inflate the safety and efficacy of drugs.

• The FDA has approved the first mRNA-based flu vaccine, developed by Moderna, specifically for adults aged 50 and older. • Former FDA vaccine regulator Jesse Goodman noted the shot's documented superiority in effectiveness over standard doses for the 50-64 age group, particularly those with underlying health conditions.

• The FDA has approved Moderna's mFLUSIVA, the first seasonal influenza vaccine utilizing mRNA technology to receive official authorization. • The vaccine is specifically approved for use in adults aged 50 and older, marking a significant milestone for the drugmaker's mRNA platform.

• The FDA has approved Moderna’s mFlusiva, marking the first time a licensed influenza vaccine has been developed using messenger RNA (mRNA) technology. • This approval represents a significant milestone for mRNA, a platform that gained global prominence during the COVID-19 pandemic but has faced scrutiny from vaccine skeptics.

• A new medical review suggests that reducing protein consumption may slow biological aging and extend lifespan by improving metabolism and lowering inflammation. • The research highlights that protein restriction preserves healthy cell function and reduces cellular damage, offering benefits similar to calorie restriction but without the need to limit total caloric intake.

• An FDA advisory panel has recommended the use of an experimental Replimune treatment for advanced melanoma, despite the agency having rejected the drug twice previously. • Rising oil prices driven by the conflict with Iran have sparked industry concerns regarding the vulnerability of essential medicine supply chains to price volatility.

• Gilead Sciences has successfully won a legal case regarding its HIV medication, securing a favorable ruling for the company. • Eli Lilly announced plans to expand patient access to retatrutide, a promising weight-loss and metabolic drug currently in development.